

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated December 15, 2025 (the “**Prospectus**”) issued by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技(武漢)股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.*

*Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meanings as those defined in the Prospectus.*

*Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, December 23, 2025).*

# Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

## 翰思艾泰生物醫藥科技(武漢)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

### GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 18,321,000 H Shares
Number of Hong Kong Offer Shares	: 1,832,100 H Shares
Number of International Offer Shares	: 16,488,900 H Shares
Final Offer Price	: HK\$32.00 per H Share plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars, subject to refund)
Nominal value	: RMB0.1 per H Share
Stock code	: 3378

Sole Sponsor, Overall Coordinator, Joint Global Coordinator and Joint Bookrunners

ICBC  工銀國際

Overall Coordinators, Joint Global Coordinators and Joint Bookrunners



Joint Global Coordinators and Joint Bookrunners



Joint Bookrunners



# Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

## 翰思艾泰生物醫藥科技(武漢)股份有限公司

### ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 15, 2025 (the “**Prospectus**”) issued by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰思艾泰生物醫藥科技(武漢)股份有限公司 (the “**Company**”).

*Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.*

#### SUMMARY

Company information	
Stock code	3378
Stock short name	HANXBIO-B
Dealings commencement date	December 23, 2025 <sup>#</sup>

<sup>#</sup> see note at the end of the announcement

Price Information	
Final Offer Price	HK\$32.00

Offer Shares and Share Capital	
Number of Offer Shares	18,321,000
Number of Offer Shares in Hong Kong Public Offering	1,832,100
Number of Offer Shares in International Offering	16,488,900
Number of issued shares upon Listing	136,218,830

Over-allocation	
Number of Offer Shares over-allocated	0

The Overall Coordinators confirmed that there has been no over-allocation of the Offer Shares in the International Offering. Therefore, it is expected that the Over-allotment Option will not be exercised.

Proceeds	
Gross proceeds (Note)	HK\$586.3 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$55.0 million
Net proceeds	HK\$531.3 million

*Note: Gross proceeds refers to the amount which the issuer is entitled to receive. For details of the use of proceeds, please refer to the Prospectus dated December 15, 2025.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

<b>No. of valid applications</b>	139,704
<b>No. of successful applications</b>	17,689
<b>Subscription level</b>	3,074.09 times
<b>Claw-back triggered</b>	Nil
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	1,832,100
<b>Final no. of Offer Shares under the Hong Kong Public Offering</b>	1,832,100
<b>% of final number of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10.00%

*Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to <https://www.hkeipo.hk/iporesult> to perform a search by identification number or <https://www.hkeipo.hk/iporesult> for the full list of allottees.*

### INTERNATIONAL OFFERING

<b>No. of placees</b>	65
<b>Subscription Level</b>	5.78 times
<b>No. of Offer Shares initially available under the International Offering</b>	16,488,900
<b>Final no. of Offer Shares under the International Offering</b>	16,488,900
<b>% of final number of Offer Shares under the International Offering to the Global Offering</b>	90.00%

*The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors chief executive of the Company, controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The placees in the International Offering include the following:

***Cornerstone Investors***

<b><i>Investor</i></b> <sup><i>Note</i></sup>	<b><i>No. of Offer Shares allocated</i></b>	<b><i>% of Offer Shares</i></b>	<b><i>% of total issued H share capital after the Global Offering</i></b> <sup><i>Note (1)</i></sup>	<b><i>% of total issued share capital after the Global Offering</i></b> <sup><i>Note (1)</i></sup>	<b><i>Existing Shareholders or their close associates</i></b>
Fund Resources Investment Holding Group Company Limited	1,216,100	6.64%	0.89%	0.89%	No
Sage Partners Master Fund	364,800	1.99%	0.27%	0.27%	No
Guotai Junan Investments (Hong Kong) Limited (“GTINV”) (in connection with the Kunyang OTC Swaps)	343,700	1.88%	0.25%	0.25%	No
TFI Investment Fund SPC (acting for and on behalf of its segregated portfolio, TFI Lakeside SP)	312,500	1.71%	0.23%	0.23%	No
Main Source Capital Limited	312,500	1.71%	0.23%	0.23%	No
YStem Holding Limited	243,200	1.33%	0.18%	0.18%	No
Awaken Thunder Capital Limited	125,000	0.68%	0.09%	0.09%	No
<b>Total</b>	<b>2,917,800</b>	<b>15.93%</b>	<b>2.14%</b>	<b>2.14%</b>	<b>–</b>

***Notes:***

- (1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).
- (2) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.

## Allottees with waivers/consents obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i> <sup>Note (1)</sup>	<i>% of total issued share capital after the Global Offering</i> <sup>Note (1)</sup>	<i>Relationship</i> <sup>Note (2)</sup>
<b>Allottees with consent under paragraphs 1C(1) and 1B(7) of the Placing Guidelines and paragraphs 5 and 6 of Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected clients</b>					
GTINV	1,739,000	9.49%	1.28%	1.28%	Connected client
Huatai Capital Investment Limited (“HTCI”)	1,555,200	8.49%	1.14%	1.14%	Connected client
<b>Total</b>	<b>3,294,200</b>	<b>17.98%</b>	<b>2.42%</b>	<b>2.42%</b>	<b>–</b>
<b>Notes:</b>  (1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).  (2) For details of the consent under paragraphs 1C(1) and 1B(7) of the Placing Guidelines and paragraphs 5 and 6 of Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected clients, please refer to the section headed “Others/Additional Information – Placing to connected clients with prior consents under paragraphs 1C(1) and 1B(7) of the Placing Guidelines” in this announcement.					

## LOCK-UP UNDERTAKINGS

### Controlling Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of shares in the Company held through controlled corporation and subject to lock-up undertakings upon Listing</i>	<i>Number of H shares in the Company held in the Company or through controlled corporation and subject to lock-up undertakings upon Listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>Last day subject to the lock-up undertakings</i> <sup>Note (5)</sup>
Cai Zhang Biotechnology (Hangzhou) Co., Ltd. (“CZ Biotechnology”) <sup>Note (2)</sup>	55,300,000	–	55,300,000	40.60%	40.60%	December 22, 2026
Zhang Faming <sup>Note (2)</sup>	–	55,300,000	55,300,000	40.60%	40.60%	December 22, 2026
Luo Fang <sup>Note (2)</sup>	–	55,300,000	55,300,000	40.60%	40.60%	December 22, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of shares in the Company held through controlled corporation and subject to lock-up undertakings upon Listing</i>	<i>Number of H shares in the Company held in the Company or through controlled corporation and subject to lock-up undertakings upon Listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i> <i>Note (1)</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i> <i>Note (1)</i>	<i>Last day subject to the lock-up undertakings</i> <i>Note (5)</i>
Hanx Biopharmaceuticals (HK) Limited (“ <b>Hanx Biopharmaceuticals (HK)</b> ”) <i>Note (3)</i>	17,793,640	–	17,793,640	13.06%	13.06%	December 22, 2026
Caizhang Vision Limited <i>Note (3)</i>	–	17,793,640	17,793,640	13.06%	13.06%	December 22, 2026
HanX Biopharmaceuticals Limited (“ <b>HanX Biopharmaceuticals</b> ”) <i>Note (3)</i>	–	17,793,640	17,793,640	13.06%	13.06%	December 22, 2026
HanxBio (BVI) Limited (“ <b>HanxBio (BVI)</b> ”) <i>Note (3)</i>	–	17,793,640	17,793,640	2.24%	2.24%	December 22, 2026
Wuhan Hanx Tai Management Consulting Partnership (Limited Partnership) (“ <b>Wuhan Hanx</b> ”) <i>Note (4)</i>	3,045,070	–	3,045,070	2.24%	2.24%	December 22, 2026
<b>Total</b>			<b>76,138,710</b>	<b>55.89%</b>	<b>55.89%</b>	<b>–</b>

*Notes:*

- (1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).
- (2) CZ Biotechnology is legally and beneficially owned as to 99.9% by Dr. Zhang and 0.1% by Ms. Luo Fang. CZ Biotechnology, Ms. Luo Fang and Dr. Zhang are considered as a group of controlling shareholders of our Group pursuant to the Listing Rules.
- (3) Hanx Biopharmaceuticals (HK) is controlled by HanxBio (BVI), which is in turn controlled by Hanx Biopharmaceuticals. Hanx Biopharmaceuticals is controlled by Caizhang Vision, which is controlled by Dr. Zhang.
- (4) Wuhan Hanx is owned as to 75% by CZ Biotechnology, who is also the general partner of Wuhan Hanx.
- (5) The expiry date of the lock-up period shown in the table above is pursuant to the statutory lock-up requirements under the PRC Company Law.

## Cornerstone Investors

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>Last day subject to the lock-up undertakings</i> <sup>Note (3)</sup>
Fund Resources Investment Holding Group Company Limited	1,216,100	1,216,100	0.88%	0.88%	June 22, 2026
Sage Partners Master Fund	364,800	364,800	0.26%	0.26%	June 22, 2026
GTINV (in connection with the Kunyang OTC Swaps)	343,700	343,700	0.25%	0.25%	June 22, 2026
TFI Investment Fund SPC (acting for and on behalf of its segregated portfolio, TFI Lakeside SP)	312,500	312,500	0.22%	0.22%	June 22, 2026
Main Source Capital Limited	312,500	312,500	0.22%	0.22%	June 22, 2026
YStem Holding Limited	243,200	243,200	0.18%	0.18%	June 22, 2026
Awaken Thunder Capital Limited	125,000	125,000	0.09%	0.09%	June 22, 2026
<b>Total</b>	<b>2,917,800</b>	<b>2,917,800</b>	<b>2.10%</b>	<b>2.10%</b>	<b>–</b>
<p><i>Notes:</i></p> <p>(1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).</p> <p>(2) In accordance with the relevant cornerstone investment agreements, the required lock-up ends on June 22, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares after the indicated date.</p> <p>(3) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.</p>					



***Pre-IPO Investors (as defined in the “History and Corporate Structure” section of the Prospectus)***

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i> <sup>Note (1)</sup>	<i>Last day subject to the lock-up undertakings</i> <sup>Note (3)</sup>
Hangzhou Hongye Ruiji Investment Partnership (Limited Partnership)* (杭州紅業睿吉投資合夥企業(有限合夥))	12,860,470	12,860,470	9.44%	9.44%	December 22, 2026
Beijing Lapam Biopharmaceutical Venture Capital Center (Limited Partnership)* (北京龍磐生物醫藥創業投資中心(有限合夥)) <sup>Note (2)</sup>	12,860,470	12,860,470	9.44%	9.44%	December 22, 2026
Tibet Lapam Small and Medium Enterprise Development Fund Equity Investment Partnership (Limited Partnership)* (西藏龍磐中小企業發展基金股權投資合夥(有限合夥)) <sup>Note (2)</sup>	1,195,620	1,195,620	0.88%	0.88%	December 22, 2026
Betta Pharmaceuticals Co., Ltd.	6,430,230	6,430,230	4.72%	4.72%	December 22, 2026
Wuhan Donggaorensi Equity Investment Partnership (Limited Partnership)* (武漢市東高仁思股權投資合夥企業(有限合夥))	3,416,060	3,416,060	2.51%	2.51%	December 22, 2026
Hangzhou Taikun Equity Investment Fund Partnership (Limited Partnership) (杭州泰鯤股權投資基金合夥企業(有限合夥))	2,562,050	2,562,050	1.88%	1.88%	December 22, 2026
Yangtze Investment (HK) Limited	1,804,020	1,804,020	1.32%	1.32%	December 22, 2026
Lapam Capital HK Co., Limited <sup>Note (2)</sup>	596,040	596,040	0.44%	0.44%	December 22, 2026
Xiao Jieyu	11,100	11,100	0.0081%	0.0081%	December 22, 2026
Zou Zhiyong	1,710	1,710	0.0013%	0.0013%	December 22, 2026
Liao Tong	21,350	21,350	0.0157%	0.0157%	December 22, 2026
<b>Total</b>	<b>41,759,120</b>	<b>41,759,120</b>	<b>30.66%</b>	<b>30.66%</b>	<b>–</b>

***Note:***

- (1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).
- (2) Beijing Lapam, Tibet Lapam and Lapam Capital are companies controlled by Mr. Yu, a director of and a board representative of Beijing Lapam in Hangzhou Hanx, or his close associate.
- (3) The expiry date of the lock-up period shown in the table above is pursuant to the statutory lock-up requirements under the PRC Company Law.

**PLACEE CONCENTRATION ANALYSIS**

Placees	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	2,435,000	14.77%	13.29%	2,435,000	1.79%
Top 5	7,202,800	43.68%	39.31%	7,202,800	5.29%
Top 10	10,567,800	64.09%	57.68%	10,567,800	7.76%
Top 25	14,431,300	87.52%	78.77%	14,431,300	10.59%

*Note:*

1. Ranking of placees is based on the number of H Shares allotted to the placees.

**H SHAREHOLDERS CONCENTRATION ANALYSIS**

H Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	76,138,710	55.89%	76,138,710
Top 5	0	0.00%	0.00%	113,497,600	88.32%	113,497,600
Top 10	4,867,200	29.52%	26.57%	122,730,870	90.10%	122,730,870
Top 25	13,089,600	79.38%	71.45%	130,953,270	96.13%	130,953,270

*Note:*

1. Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

**SHAREHOLDER CONCENTRATION ANALYSIS**

Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	76,138,710	76,138,710	55.89%
Top 5	0	0.00%	0.00%	113,497,600	113,497,600	88.32%
Top 10	4,867,200	29.52%	26.57%	122,730,870	122,730,870	90.10%
Top 25	13,089,600	79.38%	71.45%	130,953,270	130,953,270	96.13%

*Note:*

1. Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

## ***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
<b>POOL A</b>			
100	35,303	354 OUT OF 35,303 applicants to receive 100 Shares	1.00
200	7,318	107 OUT OF 7,318 applicants to receive 100 Shares	0.73
300	25,336	459 OUT OF 25,336 applicants to receive 100 Shares	0.60
400	2,536	54 OUT OF 2,536 applicants to receive 100 Shares	0.53
500	2,610	63 OUT OF 2,610 applicants to receive 100 Shares	0.48
600	1,780	47 OUT OF 1,780 applicants to receive 100 Shares	0.44
700	1,253	36 OUT OF 1,253 applicants to receive 100 Shares	0.41
800	1,061	33 OUT OF 1,061 applicants to receive 100 Shares	0.39
900	1,521	50 OUT OF 1,521 applicants to receive 100 Shares	0.37
1,000	7,041	245 OUT OF 7,041 applicants to receive 100 Shares	0.35
1,500	7,144	309 OUT OF 7,144 applicants to receive 100 Shares	0.29
2,000	2,044	104 OUT OF 2,044 applicants to receive 100 Shares	0.25
2,500	1,316	75 OUT OF 1,316 applicants to receive 100 Shares	0.23
3,000	1,687	106 OUT OF 1,687 applicants to receive 100 Shares	0.21
3,500	1,049	72 OUT OF 1,049 applicants to receive 100 Shares	0.20
4,000	855	63 OUT OF 855 applicants to receive 100 Shares	0.18
4,500	560	44 OUT OF 560 applicants to receive 100 Shares	0.17
5,000	1,336	111 OUT OF 1,336 applicants to receive 100 Shares	0.17
6,000	1,115	102 OUT OF 1,115 applicants to receive 100 Shares	0.15
7,000	848	85 OUT OF 848 applicants to receive 100 Shares	0.14
8,000	727	78 OUT OF 727 applicants to receive 100 Shares	0.13
9,000	639	73 OUT OF 639 applicants to receive 100 Shares	0.13
10,000	4,751	572 OUT OF 4,751 applicants to receive 100 Shares	0.12
20,000	2,935	514 OUT OF 2,935 applicants to receive 100 Shares	0.09
30,000	2,285	498 OUT OF 2,285 applicants to receive 100 Shares	0.07
40,000	1,704	434 OUT OF 1,704 applicants to receive 100 Shares	0.06
50,000	1,310	376 OUT OF 1,310 applicants to receive 100 Shares	0.06
60,000	949	301 OUT OF 949 applicants to receive 100 Shares	0.05
70,000	978	337 OUT OF 978 applicants to receive 100 Shares	0.05
80,000	893	331 OUT OF 893 applicants to receive 100 Shares	0.05
90,000	777	307 OUT OF 777 applicants to receive 100 Shares	0.04
100,000	6,765	2,821 OUT OF 6,765 applicants to receive 100 Shares	0.04
<b>Total</b>	<b>128,426</b>	<b>Total number of Pool A successful applicants: 9,161</b>	

NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
<b>POOL B</b>			
200,000	5,676	3,406 OUT OF 5,676 applicants to receive 100 Shares	0.03
300,000	1,527	1,176 OUT OF 1,527 applicants to receive 100 Shares	0.03
400,000	927	809 OUT OF 927 applicants to receive 100 Shares	0.02
500,000	731	720 OUT OF 731 applicants to receive 100 Shares	0.02
600,000	401	100 Shares	0.02
700,000	373	100 Shares plus 68 OUT OF 373 applicants to receive an additional 100 Shares	0.02
800,000	394	100 Shares plus 107 OUT OF 394 applicants to receive an additional 100 Shares	0.02
916,000	1,249	100 Shares plus 457 OUT OF 1,249 applicants to receive an additional 100 Shares	0.01
<b>Total</b>	<b><u>11,278</u></b>	<b>Total number of Pool B successful applicants: 8,528</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

### **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

### **OTHERS/ADDITIONAL INFORMATION**

#### **Placing to connected clients with prior consents under paragraphs 1C(1) and 1B(7) of the Placing Guidelines**

The Company has applied for, and the Stock Exchange has granted, consents under paragraph 1C(1) and 1B(7) of the Placing Guidelines to permit allocation to connected clients pursuant to the Placing Guidelines. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consents granted by the Stock Exchange. Details of the placement to connected clients (including the cornerstone tranche and placing tranche) are set out below.

No.	Connected Distributor	Connected Client	Relationship	Whether the Connected Client will hold the beneficial interests of the Offer Shares on a nondiscretionary basis or discretionary basis for independent third parties	Number of Offer Shares to be allocated to the connected client	Approximate percentage of Offer Shares allocated to the connected client <sup>Note (1)</sup>	Approximate percentage of total issued share capital after the Global Offering <sup>Note (1)</sup>
1.	Haitong International Securities Company Limited (“HTI”)	GTINV (in connection with the Kuyang OTC Swaps) <sup>Note (2)</sup>	GTINV is a member of same group of HTI	Non-discretionary basis	343,700	1.88%	0.25%
2.	HTI	GTINV (in connection with TRS arrangement with Hainan Leixuan Private Equity Fund Management Partnership (Limited Partnership)* (海南磊暄私募基金管理合伙企业(有限合伙)) <sup>Note (3)</sup>	GTINV is a member of same group of HTI	Non-discretionary basis	1,395,300	7.62%	1.02%
3.	Huatai Financial Holdings (Hong Kong) Limited (“HTFH”)	HTCI (in connection with TRS arrangement with Leixuan Jinyang Private Equity Investment Fund* (磊暄金陽私募證券投資基金)) <sup>Note (4)</sup>	HTCI is a member of same group of HTFH	Non-discretionary basis	1,039,700	5.67%	0.76%

<b>No.</b>	<b>Connected Distributor</b>	<b>Connected Client</b>	<b>Relationship</b>	<b>Whether the Connected Client will hold the beneficial interests of the Offer Shares on a nondiscretionary basis or discretionary basis for independent third parties</b>	<b>Number of Offer Shares to be allocated to the connected client</b>	<b>Approximate percentage of Offer Shares allocated to the connected client<sup>Note (1)</sup></b>	<b>Approximate percentage of total issued share capital after the Global Offering<sup>Note (1)</sup></b>
4.	HTFH	HTCI (in connection with TRS arrangement with Aifang Jinke No. 3 Private Securities Investment Fund* (艾方金科 3 號私募基金)) <sup>Note (4)</sup>	HTCI is a member of same group of HTFH	Non-discretionary basis	485,500	2.65%	0.36%
5.	HTFH	HTCI (in connection with TRS arrangement with Xingchen Aifang Multi-Strategy No. 17 Private Securities Investment Fund* (星辰之艾方多策略 17 號私募基金)) <sup>Note (4)</sup>	HTCI is a member of same group of HTFH	Non-discretionary basis	30,000	0.16%	0.02%



Note:

- (1) The calculation is based on the total number of 136,218,830 H Shares in issue upon Listing (comprising (i) an aggregate of 117,897,830 Shares to be converted from Unlisted Shares; and (ii) 18,321,000 Shares to be issued pursuant to the Global Offering).
- (2) For details regarding the consent obtained in respect of the allocations to GTINV as a connected client in connection with the Kunyang OTC Swap under paragraphs 1C(1) and 1B(7) of the Placing Guidelines and paragraphs 5 and 6 of Chapter 4.15 of the Guide for New Listing Applicants, please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with The Companies (Winding Up And Miscellaneous Provisions) Ordinance – Consent in respect of the Proposed Subscription of H Shares by a Connected Client – Guotai Junan Investments (Hong Kong) Limited (in connection with the Kunyang OTC Swaps)” in the Prospectus.
- (3) GTINV shall hold the Offer Shares for hedging purpose as the single underlying asset of several sets of back-to-back total return swap transaction (the “**GTHT Back-to-back TRS**”) to be entered into between GTINV and Guotai Haitong Securities Co., Ltd. (the “**GTHT Onshore Parent**”) in connection with several total return swap orders (the “**GTHT Client TRS**”) to be entered into by GTHT Onshore Parent and Hainan Leixuan Private Equity Fund Management Partnership (Limited Partnership)\* (海南磊暄私募基金管理合夥企業(有限合夥)) (the “**GTHT Onshore Ultimate Client**”), respectively. Such GTHT Client TRS is to be fully funded by the GTHT Onshore Ultimate Client. GTINV will hold the Offer Shares on a non-discretionary basis for the purpose of hedging the economic exposure under the GTHT Back-to-back TRS and GTHT Client TRS only. During the tenor of the GTHT Client TRS, all economic returns of the Offer Shares will be passed to the GTHT Onshore Ultimate Client and all economic losses shall be borne by the GTHT Onshore Ultimate Client, subject to the terms and conditions of the GTHT Back-to-back TRS and GTHT Client TRS, and GTINV will not take part in any economic return or bear any economic loss in relation to the price of the Offer Shares. The GTHT Onshore Ultimate Client may request to redeem the Offer Shares at their own discretion, upon which GTINV shall dispose of the Offer Shares and settle the GTHT Back-to-back TRS and GTHT Client TRS in cash in accordance with the terms and conditions of the GTHT Back-to-back TRS and GTHT Client TRS documents. Due to its internal policy, GTINV will not exercise the voting right attaching to the Offer Shares during the tenor of the GTHT Back-to-back TRS and GTHT Client TRS. To the best knowledge of GTINV and after making all reasonable enquiries, (i) Song Chengfei (宋誠菲) holds more than 30% in interest in the GTHT Onshore Ultimate Client, (ii) the GTHT Onshore Ultimate Client and the ultimate beneficial owner holding 30% or more interest of the GTHT Onshore Ultimate Client listed above is an independent third party of GTINV, HTI and the companies which are members of the same group of companies as HTI.
- (4) PRC investors are currently not permitted under applicable PRC laws to participate directly in initial public offerings (“**IPOs**”) in Hong Kong. However, PRC investors are permitted to invest in products issued by appropriate domestic securities firms licensed to undertake cross-border derivatives trading activities. In connection with such products, the licensed domestic securities firms, through their Hong Kong affiliates, may participate in Hong Kong IPOs either as placees or cornerstone investors (the “**Cross-border Derivatives Trading Regime**”).

Huatai Securities Co., Ltd. (“**Huatai Securities**”), the shares of which are listed on both the Shanghai Stock Exchange (stock code: 601688) and the Stock Exchange (stock code: 6886), is one of the domestic securities firms licensed to undertake cross-border derivatives trading activities. Huatai Securities entered into an ISDA agreement (the “**ISDA Agreement**”) with its indirectly wholly-owned subsidiary, Huatai Capital Investment Limited (“**HTCI**”) to set out the principal terms of any future total return swap between Huatai Securities and HTCI.

HTFH is a non-syndicate distributor in connection with the Global Offering. Pursuant to the ISDA Agreement, HTCI, which intends to participate in the Global Offering as a placee, will hold the beneficial interest of the Offer Shares on a non-discretionary basis as the single underlying holder under a back-to-back total return swap (the “**Back-to-back TRS**”) to be entered by HTCI in connection with a Client TRS (as defined below) placed by and fully funded (i.e. with no financing provided by HTCI) by the Huatai Ultimate Client (as defined below), by which, HTCI will, subject to customary fees and commissions, pass the full economic exposure of the Offer Shares ultimately to the Huatai Ultimate Client, which in effect, HTCI will hold the beneficial interest of the Offer Shares on behalf of the Huatai Ultimate Clients. HTFH, the non-syndicate distributor and HTCI are indirectly wholly-owned subsidiaries of Huatai Securities. Accordingly, HTCI is considered as a “connected client” of HTFH pursuant to Paragraph 1B(7) of Appendix F1 of the Listing Rules.

Pursuant to the Cross-border Derivatives Trading Regime, the onshore investors (the “**Huatai Ultimate Clients**”) cannot directly subscribe for the Offer Shares but may invest in derivative products issued by domestic securities firms licenced to undertake cross-border derivatives trading activities, such as Huatai Securities, with the Offer Shares as the underlying assets. Instead of directly subscribing for the Offer Shares, the Huatai Ultimate Clients will, through their investment managers, place a total return swap order (the “**Client TRS**”) with Huatai Securities in connection with the Company’s IPO and Huatai Securities will place a Back-to-back TRS order to HTCI on the terms of the ISDA Agreement. In order to hedge its exposure under the Back-to-back TRS, HTCI participates in the Company’s IPO and subscribes the Offer Shares through placing order with HTFH during the International Offering.

To the best knowledge of HTCI and after making all reasonable enquiries, (i) the Huatai Ultimate Clients are (a) Leixuan Jinyang Private Equity Investment Fund\* (磊喧金陽私募證券投資基金) in which Song Chengfei (宋誠菲) holds more than 30% interest, (b) Aifang Jinke No. 3 Private Securities Investment Fund\* (艾方金科3號私募證券投資基金) in which Leng Ling (冷玲) holds more than 30% interest, and (c) Xingchen Aifang Multi-Strategy No. 17 Private Securities Investment Fund\* (星辰之艾方多策略17號私募證券投資基金) in which Min Yuan (閔淵) and Huang Yuan (黃源) hold more than 30% interest; (ii) each of the Huatai Ultimate Clients is an independent third parties of the Company, its subsidiaries and substantial shareholders, HTFH, HTCI, and the companies which are members of the same group of companies as HTFH, and (ii) HTCI is not a collective investment scheme which is not authorised by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.

The purpose of HTCI to subscribe for the Offer Shares is for hedging the Back-to-back TRS in connection with the Client TRS order placed by the Huatai Ultimate Clients. Pursuant to the terms of the contracts of the Back-to-back TRS and the Client TRS, during the tenor of the Back-to-back TRS and the Client TRS, subject to customary fees and commissions, all economic returns of the Offer Shares will be ultimately passed to the Huatai Ultimate Clients through the Back-to-back TRS and the Client TRS and all economic loss shall be ultimately borne by the Huatai Ultimate Clients. HTCI will not take any economic return or bear any economic loss in relation to the Offer Shares.

Investment in the Back-to-back TRS and the Client TRS is similar to the investment in a qualified domestic institutional investor fund (“**QDII**”) in the way that the Huatai Ultimate Clients would reap all the economic benefits of the underlying Offer Shares, except that a QDII fund would pass through the exchange rate exposure on both the notional value of the investment and the profit and loss of the investment. In contrast, the profit and loss of the Back-to-back TRS and the Client TRS factor into account the fluctuation in RMB exchange rate upon termination of the Client TRS by converting the profit and loss using the current exchange rate at the time of termination. As such, the Huatai Ultimate Clients would bear the exchange rate exposure of the profit and loss on settlement date.

The Huatai Ultimate Clients may exercise an early termination right to terminate the Client TRS at any time from the issue date of the Client TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange at its own discretion. Upon the termination upon maturity or early termination of the Client TRS by the Huatai Ultimate Clients, HTCI will dispose of the Offer Shares on the secondary market and the Huatai Ultimate Clients will receive a final settlement amount in cash in accordance with the terms and conditions of the Back-to-back TRS and the Client TRS which should have taken into account all the economic returns or economic loss in relation to the Offer Shares. If upon the maturity of the Client TRS, the Huatai Ultimate Clients intend to extend the investment period, subject to further agreement between Huatai Securities and the relevant Huatai Ultimate Clients, the term of the Client TRS could be extended by way of a new issuance or a tenor extension. Accordingly, Huatai Securities will extend the term of the Back-to-back TRS by way of a new issuance or a tenor extension.

It is proposed that HTCI will hold the legal title and the voting right of the Offer Shares by itself, and pass through the economic exposure to the Huatai Ultimate Clients, each being an onshore client who places a Client TRS order with Huatai Securities in connection with the IPO of the Company. HTCI will not exercise the voting right of the Offer Shares during the tenor of the Back-to-back TRS.

During the life of the Client TRS and Back-to-back TRS, HTCI may continue to hold the Offer Shares in its custodian account, or to hold some or all of the Offer Shares in a prime brokerage account for stock borrowing purposes, where HTCI will lend out its holding of underlying Offer Shares in the form of stock borrowing loans consistent with market practice to lower its finance costs, provided that HTCI has the ability to call back the Offer Shares on loan at any time in order to satisfy its obligations under the Back-to-back TRS to ensure the economic interests are ultimately passed to the Huatai Ultimate Clients.



## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act or any state securities law of the United States. The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated December 15, 2025 issued by Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技(武漢)股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*# Potential investors of the Offer Shares should note that the the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, December 23, 2025).*

## **PUBLIC FLOAT AND FREE FLOAT**

Immediately following the completion of the Global Offering, an aggregate of 45,416,890 Shares, representing approximately 33.3% of the issued share capital of our Company will be counted towards the public float, which is not less than the prescribed percentage of Shares required to be held in public hands of 25% under Rule 19A.13A of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the Shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

Based on an Offer Price of HK\$32.00 per Offer Share, the Company will satisfy the free float requirement under Rule 19A.13C(1) of the Listing Rules.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, December 23, 2025, provided that the Global Offering has become unconditional in all aspects and the right of termination described in the section “Underwriting — Underwriting Arrangements and Expenses — Grounds for termination” in the Prospectus has not been exercised and has lapsed. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, December 23, 2025, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, December 23, 2025. The H Shares will be traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 3378.

By order of the Board  
**Hanx Biopharmaceuticals (Wuhan) Co., Ltd.**  
**Dr. ZHANG Faming**  
*Chairman and Executive Director*

Hong Kong, December 22, 2025

*As at the date of this announcement, the Board of Directors of the Company comprises: (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.*

\* *For identification purpose only*